Diálisis de albúmina de paso único (SPAD) como soporte hepático extracorpóreo en paciente COVID-19 crítico. Caso clínico

• Gonzalo Ramírez-Guerrero ^[1] ; Anita Zurita-Poza ; Romyna Baghetti-Hernández ; Francisco Villagrán-Cortés ; Bárbara Segovia-Hernández ; Lisette Aguirre-Adones ; Osvaldo Garay
  1. [1] Universidad de Valparaíso Facultad de Medicina Departamento de Medicina Interna
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 150, Nº. 11, 2022, págs. 1540-1544
• Idioma: español
• Títulos paralelos:
  • Single-pass albumin dialysis as treatment of acute on chronic liver failure during COVID-19 pneumonia. report of one case
• Enlaces
  • Texto completo
• Resumen

  • Liver transplantation is the only effective therapy to reduce the high mortality associated with acute liver failure and acute on chronic liver failure (ACLF). Single-pass albumin dialysis (SPAD) is an extracorporeal supportive therapy used as a bridge to liver transplantation or regeneration. We report a 44-year-old man with alcoholic cirrhosis admitted for critical COVID-19 pneumonia that evolves with ACLF. SPAD technique was performed completing six sessions, with a reduction of bilirubin and ammonia levels. He evolved with severe respiratory failure and refractory septic shock, dying. SPAD is a safe and efficient technique aimed to eliminate liver toxins, preventing multiorgan damage interrupting the process known as the "autointoxication hypothesis". It is easy to implement in any critical patient unit and has lower costs than other extracorporeal liver support therapies.